The report’s authors assessed commercial plan coverage and formulary design concerning biosimilars for the top 25 payers—covering approximately 189 million lives—in the United States, using publicly available policies.
Avalere has issued a new report that finds that utilization management strategies, including preferential formulary design and step therapy, are impacting the uptake of biosimilars in the United States.
While the Congressional Budget Office (CBO) in 2009 projected that the United States could achieve a $5.9 billion savings from biosimilars over 10 years, Avalere estimates the actual savings realized since the inception of the US biosimilars pathway at just $241 million, or 8% of the CBO’s projection for the period. (Notably, the savings estimate includes savings from tbo-filgrastim, which was not approved as a biosimilar but as a follow-on version of filgrastim.) While there are multiple factors at work that have led to somewhat disappointing cost-savings, the report suggests that payer policies are playing a significant role.
The report’s authors assessed commercial plan coverage and formulary design concerning biosimilars for the top 25 payers—covering approximately 189 million lives—in the United States, using publicly available policies. For each plan, they sought to determine the order of therapy (or step therapy) for biosimilars or other products in a given indication. Namely, they identified whether a particular product was the preferred first step, whether a patient had to use that product for a specified period of time before changing to the next preferred step or steps, and whether there were exceptions allowed.
Of the plans reviewed, 18 had available documents related to infliximab and its biosimilars:
The report highlights the fact that, in many cases of step therapy that require a patient to start with a reference biologic, the biosimilar of the same product will only be covered if the patient fails to respond adequately to the reference. This practice, they note, contradicts the European League Against Rheumatism’s recommendations that switching to another drug—not a biosimilar of the same drug—may be appropriate in the case of treatment failure.
The same 18 plans had medical benefit information available for filgrastim and its biosimilar (Avalere did not include tbo-filgrastim in this portion of the analysis):
The authors write that, while it is to be expected that payers will act to protect their short- to medium-term cost-savings interests by employing utilization management strategies to biosimilars, “The extent to which such policies are necessary, will continue to be put in place, and/or will be effective, remains to be seen,” and the clinical appropriateness of such policies will need to be evaluated.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.